WELCOME TO THE DR. CHRISTIAN SCHULZE RESEARCH GROUP!
We welcome you to our website and invite you to explore our work in clinical and translational cardiovascular research!
Our group is devoted to a clinical-translational approach to study basic mechanisms of metabolism in cardiovascular disease states. In particular, our group focuses on abnormal glucose, amino acid and lipid metabolism including pathways of lipotoxicity in various tissues such as skeletal muscle, adipose tissue and myocardium in advanced cardiac disease.
On a clinical-translational level, we are employing a systematic assessment of body composition and functional performance of patients with cardiovascular disease. Our clinical exercise lab is equipped to study skeletal muscle function using advanced physiologic muscle testing methods (BIODEX). Through a systematic analysis, we define markers of muscle performance (strength and fatigability) in a number of patient cohorts. Further, we routinely perform skeletal muscle biopsies on patients. We are establishing a large serum and tissue biomarker database on patients with heart failure, patients with heart failure before and after undergoing left ventricular assist device placement and patients after cardiac transplantation.
The basic science lab employs a wide range of techniques including molecular and cell biology, histology and immunohistochemistry, lipid mass spectroscopy, structural biology and basic muscle and cardiac physiology. We study genetically altered animal models of abnormal human metabolism associated with cardiomyopathies and vascular disease as well as models of cardiac ischemia, hypertrophy and failure.
As Director of Research at the Center of Advanced Cardiac Care at Columbia University, Dr. Schulze supervises the Geier Clinical Research Center. In collaboration with other investigators at Columbia University, we direct several phase 2 and 3 clinical trials that cover all aspects of pharmacologic, cell and genomic as well as device-based clinical interventions in patients with heart failure.
As a clinical-translational research group, we are looking for ways to ultimately turn clinical or basic scientific observations into new therapeutic options for patients suffering from cardiovascular disease. Our first clinical trial to study the impact of a metabolic intervention on clinical outcomes in patients with advanced heart failure (GLUTFISH) has finished recruitment and analysis.
Our group is devoted to a clinical-translational approach to study basic mechanisms of metabolism in cardiovascular disease states. In particular, our group focuses on abnormal glucose, amino acid and lipid metabolism including pathways of lipotoxicity in various tissues such as skeletal muscle, adipose tissue and myocardium in advanced cardiac disease.
On a clinical-translational level, we are employing a systematic assessment of body composition and functional performance of patients with cardiovascular disease. Our clinical exercise lab is equipped to study skeletal muscle function using advanced physiologic muscle testing methods (BIODEX). Through a systematic analysis, we define markers of muscle performance (strength and fatigability) in a number of patient cohorts. Further, we routinely perform skeletal muscle biopsies on patients. We are establishing a large serum and tissue biomarker database on patients with heart failure, patients with heart failure before and after undergoing left ventricular assist device placement and patients after cardiac transplantation.
The basic science lab employs a wide range of techniques including molecular and cell biology, histology and immunohistochemistry, lipid mass spectroscopy, structural biology and basic muscle and cardiac physiology. We study genetically altered animal models of abnormal human metabolism associated with cardiomyopathies and vascular disease as well as models of cardiac ischemia, hypertrophy and failure.
As Director of Research at the Center of Advanced Cardiac Care at Columbia University, Dr. Schulze supervises the Geier Clinical Research Center. In collaboration with other investigators at Columbia University, we direct several phase 2 and 3 clinical trials that cover all aspects of pharmacologic, cell and genomic as well as device-based clinical interventions in patients with heart failure.
As a clinical-translational research group, we are looking for ways to ultimately turn clinical or basic scientific observations into new therapeutic options for patients suffering from cardiovascular disease. Our first clinical trial to study the impact of a metabolic intervention on clinical outcomes in patients with advanced heart failure (GLUTFISH) has finished recruitment and analysis.
